Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2001-09-28
2009-08-04
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C536S023100, C514S001000
Reexamination Certificate
active
07569551
ABSTRACT:
Administration of antisense oligodeoxynucleotides (ODN) targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene can reduce the amount of TRPM-2 in renal cell cancer (RCC) cells and other cancer cells, and as a result enhance chemosensitivity of these cells to chemotherapy agents and radiation. Thus, for example, the sensitivity of renal cell cancer cells to a chemotherapeutic agent can be increased by exposing renal cell cancer cells to a chemotherapeutic agent and an agent which reduces the amount of TRPM-2 in the renal cell cancer cells. This provides an improved method for treatment of renal cell cancer, which is generally resistant to treatment with known chemotherapy agents.
REFERENCES:
patent: 5563255 (1996-10-01), Monia et al.
patent: 5646042 (1997-07-01), Stinchcomb et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5929040 (1999-07-01), Werther et al.
patent: 5998148 (1999-12-01), Bennett et al.
patent: 6172216 (2001-01-01), Bennett et al.
patent: WO 00/49937 (2000-08-01), None
patent: WO 02/22635 (2002-03-01), None
patent: WO 03/062421 (2003-07-01), None
patent: WO 03/072591 (2003-09-01), None
Agrawal et al. Molecular Medicine Today, 2000, vol. 6, p. 72-81.
Branch TIBS 1998, vol. 23, p. 45-50.
Jen et al. Stem Cells 2000, vol. 18, p. 307-319.
Crooke, Antisense Research and Application, Chapter 1, Springer-Verlag, New York, 1998.
Opalinska et al. Nature Reviews Drug Discovery, 2002, vol. 1, p. 503-514.
Raghavan et al. European Journal of Cancer 1997, vol. 33, pp. 566-574.
Gleave et al., Use of Antisense Oligonucleotides Targeting the Antiapoptotic Gene, Clusterin/Testosterone-Repressed Prostate Message 2 to Enhance Androgen Sensitivity and Chemosensitivity in Prostate Cancer, Urology, 2001, pp. 39-49, vol. 58, XP-002262320.
Gleave et al., Antisense therapy; Current status in prostate cancer and other malignancies, Cancer and Metastasis Reviews, 2002, pp. 79-92, vol. 21, XP-001147871.
Gleave et al., Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer, Investigational New Drugs, 2002, pp. 145-158, vol. 20, No. 2, XP 009021411.
Gleave et al., Antisense Targets to Enhance Hormone and Cytotoxic Therapies in Advanced Prostate Cancer, Current Drug Targets, 2003, pp. 209-221, vol. 4.
Jones et al., Molecules in focus: Clusterin, The International Journal of Biochemistry & Cell Biology, 2002, pp. 427-431, vol. 34, XP002262319.
Miyake et al., Antisense TRPM-2 Oligodeoxynucleotides Chemosensitize Human Androgen-independent PC-3 Prostate Cancer Cells Both in Vitro and in Vivo, Clinical Cancer Research, 2000, pp. 1655-1663, vol. 6, No. 5, Publisher: The American Association for Cancer Research, US, XP000960694.
Miyake et al., Synergistic Chemsensitization and Inhibition of Tumor Growth and Metastasis by the Antisense Oligodenoxynucleotide Targeting Clusterin Gene in a Human Bladder Cancer Model, Clinical Cancer Research, 2001, pp. 4245-4252, vol. 7.
Miyake et al., Novel therapeutic strategy for advanced prostate cancer using antisense oligodeoxynucleotides targeting antiapoptotic genes upregulated after androgen withdrawal to delay androgen-independent progression and enhance chemosensitivity, International Journal of Urology, 2001, pp. 337-349, vol. 8, No. 7, XP002262321.
Rosenberg et al., Clusterin: Physiologic and Pathophysiologic Considerations, Int. J. Biochem. Cell Biol., 1995, pp. 633-645, vol. 27, No. 7, XP001002844.
Wilson et al., Clusterin is a secreted mammalian chaperone, TIBS, 2000, pp. 95-98, vol. 25, XP 4202536A.
Wong et al., Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration, European Journal of Biochemistry, 1994, pp. 917-925, vol. 227, No. 3, XP 001146404.
Zangemeister-Wittke et al., A Novel Bispecific Antisense Oligonucleotide Inhibiting Both bcl-2 and bcl-xL Expression Efficiently Induces Apoptosis in Tumor Cells, Clinical Cancer Research, 2000, pp. 2547-2555, vol. 6, XP-002241562.
Zellweger et al., Antitumor Activity of Antisense Clusterin Oligonucleotides is Improved in Vitro and in Vivo by Incorporation of 2'O-(2-Methoxy)Ethyl Chemistry, The Journal of Pharmacology and Experimental, 2001, pp. 934-940, vol. 298, No. 3, XP-002262318.
Zellweger et al., Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the antiapoptotic Gene Clusterin, Neoplasia, 2001, pp. 360-367, vol. 3, No. 4.
Buttyan et al., “Induction of the TRPM-2 Gene in Cells Undergoing Programmed Death”Molecular and Cellular BiologyAug. 1989, vol. 9, No. 8, pp. 3473-3481.
Millar et al., “Localization of mRNAs by in-situ hybridization to the residual body at stages IX-X of the cycle of the rat seminiferous epithelium: fact or artefact?”International Journal of Andrology,17:149-160 1994.
Darby et al., “Vascular Expression of Clusterin in Experimental Cyclosporine Nephrotoxicity”Exp Nephrol1995; 3:234-239.
Milner et al., “Selecting effective antisense reagents on combinatorial oligonucleotide arrays”Nature Biotechnologyvol. 15, Jun. 1997, pp. 537-541.
Sensibar et al., “Prevention of Cell Death Induced by Tumor Necrosis Factor alpha in LNCaP Cells by Overexpression of Sulfated Glycoprotein-2 (Clusterin),”Cancer Research.Jun. 1, 1995, vol. 55, pp. 2431-2437.
Miyake et al., “Testosterone-repressed Prostate Message-2 Is an Antiapoptotic Gene Involved in Progression to Androgen Independence in Prostate Cancer”,Cancer Research 60,Jan. 1, 2000, pp. 170-176.
Yang et al., “Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death”,Proc. Nat'l. Acad. Sci. USA,vol. 97, Issue 11, pp. 5907-5912, May 23, 2000.
Benner, et al., “Combination of Antisense Oligonucleotide and Low-Dose Chemotherapy in Hematological Malignancies”,Journal of Pharmacological and Toxicological Method,37:229-235 (1997).
Kadomatsu, et al, “Expression of sulfated glycoprotein 2 is associated with carcinogenesis induced by N-nitroso-N-methylurea in rat prostate and seminal vesicle”,Cancer ResApr. 1, 1993, 53(7):1480-1483.
Kyprianou, et al., “bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells.”,Int J Cancer,Jan. 27, 1997, 70(3):341-348.
Wright, et al., “A ribonucleotide reductase inhibitor, MDL 101, 731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts.”,Exp Cell Res,Jan. 10, 1996, 222(1):54-60.
Bruchovsky, et al., “Control of tumor progression by maintenance of apoptosis.”,Prostate Suppl.,1996, 6:13-21.
Gleave Martin
Miyake Hikeaki
Nelson Colleen
Rennie Paul S.
Zellweger Tobias
Marina Larson & Associates LLC
The University of British Columbia
Vivlemore Tracy
LandOfFree
Chemo- and radiation-sensitization of cancer by antisense... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chemo- and radiation-sensitization of cancer by antisense..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chemo- and radiation-sensitization of cancer by antisense... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4078983